Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Citadel Advisors LLC and related Citadel entities, along with founder Kenneth Griffin, disclosed a new passive stake in Cullinan Therapeutics, Inc. (CGEM) via Schedule 13G. The group now beneficially owns 3,009,126 common shares, or 5.1% of CGEM’s 59,014,667 shares outstanding as of 30 July 2025. Citadel Advisors, Citadel Advisors Holdings LP and Citadel GP LLC jointly hold 2,511,191 shares (4.3%), while market-making affiliate Citadel Securities controls 497,935 shares (0.8%). All voting and dispositive power is reported as shared; none of the entities has sole power over the stock. The filing is made under Rule 13d-1(b)/(c), signalling the position is currently passive rather than activist. Kenneth Griffin is deemed a control person through his ownership of the various Citadel general-partner entities. No intent to influence control of the issuer is stated, and the certification confirms the shares were not acquired for activist purposes. The disclosure provides investors with the first confirmation that a high-profile hedge-fund complex has crossed the 5% threshold in CGEM.